<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-1874 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-1874</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-1874</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-36.html">extraction-schema-36</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of systems that use computational or proxy metrics to make predictions or discoveries, and how those predictions compare to experimental or ground-truth validation results.</div>
                <p><strong>Paper ID:</strong> paper-277197795</p>
                <p><strong>Paper Title:</strong> Computer-Aided Drug Design and Drug Discovery</p>
                <p><strong>Paper Abstract:</strong> In the rapidly evolving landscape of pharmaceutical research, the integration of computational methods has become a cornerstone in drug discovery and development efforts [...].</p>
                <p><strong>Cost:</strong> 0.014</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e1874.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e1874.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of systems that use computational or proxy metrics to make predictions or discoveries, and how those predictions compare to experimental or ground-truth validation results.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>AlphaFold / Homology assessment</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Quality assessment of protein structures derived from homology modeling versus AlphaFold predictions</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A comparative evaluation of homology modeling and AlphaFold deep-learning structural predictions against experimental structural data, identifying cases where AlphaFold predictions diverge from experiment and arguing for hybrid computational–experimental validation.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Quality Assessment of Selected Protein Structures Derived from Homology Modeling and AlphaFold</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>AlphaFold (deep-learning structure prediction) and homology-modeling pipelines</td>
                        </tr>
                        <tr>
                            <td><strong>domain</strong></td>
                            <td>structural biology / protein modeling</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_name</strong></td>
                            <td>predicted 3D protein structure quality (model coordinates, predicted confidence metrics such as pLDDT/pTM or analogous per-residue confidence scores) / similarity metrics between predicted and experimental structures (e.g., RMSD, global similarity)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_type</strong></td>
                            <td>data-driven ML model (AlphaFold) and empirical homology-modeling (template-based modeling)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_description</strong></td>
                            <td>AlphaFold generates 3D coordinates from amino-acid sequence using a deep-learning model trained on structural databases; homology modeling generates structures by aligning target sequences to known template structures and building models by template-based reconstruction. Quality is assessed by predicted confidence scores (AlphaFold per-residue confidence) and by structural-comparison metrics when experimental structures exist.</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_metric_name</strong></td>
                            <td>experimentally determined 3D structures (X-ray crystallography / NMR / cryo-EM coordinates) and structure similarity metrics (RMSD, local/global agreement)</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_validation_method</strong></td>
                            <td>comparison of in silico 3D model coordinates to experimental structural coordinates (alignment and calculation of structure-similarity metrics), i.e., direct structural benchmarking against deposited experimental structures</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>explicit_gap_measurement</strong></td>
                            <td>Paper reports that there are identified cases where AlphaFold fails to match experimental data (qualitative statement); no quantitative aggregate gap measurements reported in this review text.</td>
                        </tr>
                        <tr>
                            <td><strong>false_positive_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_negative_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_both_proxy_and_ground_truth</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_performed</strong></td>
                            <td>computational + comparison to experimental structures (computational benchmarking against experimental ground-truth)</td>
                        </tr>
                        <tr>
                            <td><strong>number_predictions_made</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>number_experimentally_validated</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discovery_novelty</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>extrapolation_distance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cost_time</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>domain_maturity</strong></td>
                            <td>mixed — deep-learning structure prediction (AlphaFold) is mature and widely used but has recognized limitations; homology modeling is established but limited by template availability</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_failure_modes</strong></td>
                            <td>Instances where AlphaFold predictions do not match experimental structures are discussed; the review emphasizes limitations of structural modeling and the need for hybrid computational–experimental validation (qualitative failure-mode identification rather than quantified modes).</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_calibration</strong></td>
                            <td>AlphaFold provides per-residue confidence scores (implicit); the review notes mismatches with experimental data but does not provide calibrated statistics in the text provided.</td>
                        </tr>
                        <tr>
                            <td><strong>multiple_proxy_types</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_cascade</strong></td>
                            <td>computational benchmarking against experimentally solved structures (single-stage comparison); no further in vitro/in vivo cascade described in this review excerpt.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_baseline</strong></td>
                            <td>AlphaFold and homology modeling are compared qualitatively to experimental structures; the review reports cases of AlphaFold failure versus experimental data but does not present numeric baseline comparisons in the excerpt.</td>
                        </tr>
                        <tr>
                            <td><strong>domain_specific_factors</strong></td>
                            <td>limitations arise from issues in structural modeling such as regions with poor templates, conformational heterogeneity, or contexts not captured in training data; review emphasizes need for hybrid computational-experimental approaches.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e1874.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e1874.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of systems that use computational or proxy metrics to make predictions or discoveries, and how those predictions compare to experimental or ground-truth validation results.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>In silico → experimental antimicrobial pipeline</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>In silico screening against target enzymes followed by experimental antimicrobial assays for thienopyrimidine–sulfonamide hybrids</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A workflow where in silico docking/screening against target microbial enzymes prioritized candidates, and the selected hybrid compounds were subsequently synthesized and validated in experimental antimicrobial and antifungal assays.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Antimicrobial Evaluation of Sulfonamides after Coupling with Thienopyrimidine Coplanar Structure</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>In silico docking/virtual screening pipeline (structure-based virtual screening against microbial target enzymes)</td>
                        </tr>
                        <tr>
                            <td><strong>domain</strong></td>
                            <td>antibacterial / antifungal drug discovery</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_name</strong></td>
                            <td>docking score / predicted binding affinity to target enzyme(s) from molecular docking</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_type</strong></td>
                            <td>physics-based simulation (molecular docking) / empirical scoring functions</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_description</strong></td>
                            <td>Virtual screening/docking calculations against target enzymes produce poses and docking scores (binding-energy–like scores) used to rank candidate hybrid molecules; these computational metrics guide selection prior to synthesis.</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_metric_name</strong></td>
                            <td>experimental antimicrobial / antifungal activity (in vitro microbiological assays)</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_validation_method</strong></td>
                            <td>wet-lab synthesis of selected compounds followed by standard antimicrobial/antifungal assays (e.g., growth-inhibition assays, MIC determination) — described as experimental validation in the contribution summary.</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>explicit_gap_measurement</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_positive_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_negative_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_both_proxy_and_ground_truth</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_performed</strong></td>
                            <td>computational + experimental synthesis and activity testing (in vitro)</td>
                        </tr>
                        <tr>
                            <td><strong>number_predictions_made</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>number_experimentally_validated</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discovery_novelty</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>extrapolation_distance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cost_time</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>domain_maturity</strong></td>
                            <td>well-established workflow in medicinal chemistry — structure-based virtual screening followed by in vitro validation is a standard pipeline, though predictive accuracy varies by target and scoring function.</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_failure_modes</strong></td>
                            <td>Not explicitly quantified in the review; implicit failure modes include docking false positives (compounds with good docking scores but poor experimental activity) and scoring-function limitations — the contribution used experimental assays to validate candidates, illustrating the need for wet-lab confirmation.</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_calibration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>multiple_proxy_types</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_cascade</strong></td>
                            <td>computational virtual screening → synthesis → in vitro antimicrobial assays (two-stage cascade described qualitatively).</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_baseline</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>domain_specific_factors</strong></td>
                            <td>target enzyme choice, scoring-function limitations, and biological complexity of antimicrobial activity (cell permeability, efflux, metabolism) affect translation from docking score to experimental activity.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e1874.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e1874.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of systems that use computational or proxy metrics to make predictions or discoveries, and how those predictions compare to experimental or ground-truth validation results.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Nigella sativa network pharmacology</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Network pharmacology predictions for Nigella sativa mechanisms with experimental validation for breast cancer</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Network-pharmacology analyses identified candidate intersection genes/targets/pathways for Nigella sativa compounds in breast cancer, followed by experimental validation to test predicted mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Network Pharmacology and Experimental Validation to Explore the Potential Mechanism of Nigella sativa for the Treatment of Breast Cancer</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>Network pharmacology pipeline (target/pathway prediction from compound–target networks and enrichment analyses)</td>
                        </tr>
                        <tr>
                            <td><strong>domain</strong></td>
                            <td>network pharmacology / natural-product drug discovery / oncology</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_name</strong></td>
                            <td>network-derived target/pathway scores (e.g., connectivity, enrichment p-values, predicted target engagement from network topology)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_type</strong></td>
                            <td>data-driven bioinformatic network analysis (computational inference from known compound–target and gene–disease associations)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_description</strong></td>
                            <td>Computational integration of compound-target databases, gene-expression or disease-gene associations, and pathway enrichment analyses to predict relevant molecular targets and mechanisms for Nigella sativa constituents relevant to breast cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_metric_name</strong></td>
                            <td>experimental validation metrics (e.g., in vitro assays measuring cellular viability, target modulation, biochemical assays validating predicted targets/pathways)</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_validation_method</strong></td>
                            <td>wet-lab experiments testing predicted mechanisms and effects (in vitro cellular or molecular assays as described in the contribution title and summary).</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>explicit_gap_measurement</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_positive_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_negative_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_both_proxy_and_ground_truth</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_performed</strong></td>
                            <td>computational network pharmacology + experimental validation (in vitro)</td>
                        </tr>
                        <tr>
                            <td><strong>number_predictions_made</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>number_experimentally_validated</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discovery_novelty</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>extrapolation_distance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cost_time</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>domain_maturity</strong></td>
                            <td>established computational strategy in natural-product research, but translation to experimental confirmation remains challenging due to biological complexity.</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_failure_modes</strong></td>
                            <td>Not quantified in the review; general limitations include false positive pathway/target predictions owing to database incompleteness or pleiotropic effects, requiring experimental follow-up.</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_calibration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>multiple_proxy_types</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_cascade</strong></td>
                            <td>computational network analysis → targeted experimental validation (qualitative two-stage pipeline).</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_baseline</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>domain_specific_factors</strong></td>
                            <td>multi-target nature of natural products, pathway redundancy, and complexities of cellular phenotypes influence proxy-to-ground-truth translation.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e1874.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e1874.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of systems that use computational or proxy metrics to make predictions or discoveries, and how those predictions compare to experimental or ground-truth validation results.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>AutoPepVax</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>AutoPepVax, a machine-learning-based program for vaccine epitope design (application to pan-cancer EGFR missense mutations)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An ML-driven epitope selection framework using random-forest classification and linear regression to predict epitope safety, efficacy, and population applicability for vaccine design, demonstrated on EGFR missense mutations as a pan-cancer vaccine target.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>AutoPepVax, a Novel Machine-Learning-Based Program for Vaccine Design: Application to a Pan-Cancer Vaccine Targeting EGFR Missense Mutations</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>AutoPepVax (random forest classifier + linear regression models for epitope selection)</td>
                        </tr>
                        <tr>
                            <td><strong>domain</strong></td>
                            <td>vaccine design / computational immunology</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_name</strong></td>
                            <td>predicted epitope immunogenicity/safety scores and population-coverage estimates (ML-derived classification/regression outputs)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_type</strong></td>
                            <td>data-driven ML models (random forest classification, linear regression)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_description</strong></td>
                            <td>Models trained on available epitope/immune-response datasets produce classification labels (predicted safe/immunogenic epitopes) and regression scores (quantitative safety/efficacy predictions); population-coverage optimization performed computationally.</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_metric_name</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_validation_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>explicit_gap_measurement</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_positive_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_negative_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_both_proxy_and_ground_truth</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>validation_performed</strong></td>
                            <td>computational only (as reported in this review summary); no explicit wet-lab validation described in the excerpt</td>
                        </tr>
                        <tr>
                            <td><strong>number_predictions_made</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>number_experimentally_validated</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discovery_novelty</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>extrapolation_distance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cost_time</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>domain_maturity</strong></td>
                            <td>emerging ML-driven vaccine-design methods; incorporation of ML is growing but experimental validation is often required to confirm predictions.</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_failure_modes</strong></td>
                            <td>Review notes general issues in ML models for epitope selection (poor predictive accuracy historically); AutoPepVax aims to address predictive accuracy but no quantitative failure-mode statistics are provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_calibration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>multiple_proxy_types</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cascade</strong></td>
                            <td>computational epitope prediction and population-coverage analysis (no experimental cascade described in excerpt).</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_baseline</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>domain_specific_factors</strong></td>
                            <td>data quality/bias in epitope datasets, class imbalance, and limited experimental immunogenicity data affect ML predictive performance.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e1874.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e1874.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of systems that use computational or proxy metrics to make predictions or discoveries, and how those predictions compare to experimental or ground-truth validation results.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Aurora B ML repurposing</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Machine learning-assisted drug repurposing framework for discovery of Aurora Kinase B inhibitors</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A machine-learning-assisted framework intended to repurpose approved or known compounds as Aurora Kinase B inhibitors by integrating ML-based virtual screening with downstream computational analyses.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Machine Learning-Assisted Drug Repurposing Framework for Discovery of Aurora Kinase B Inhibitors</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>Machine learning-assisted drug repurposing pipeline (unspecified ML models for activity prediction and virtual screening)</td>
                        </tr>
                        <tr>
                            <td><strong>domain</strong></td>
                            <td>drug repurposing / kinase inhibitor discovery</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_name</strong></td>
                            <td>ML-predicted inhibitory activity scores / repurposing prioritization scores</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_type</strong></td>
                            <td>data-driven ML model (virtual screening/prediction)</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_metric_description</strong></td>
                            <td>ML models trained on activity/chemotype data rank existing compounds for predicted Aurora Kinase B inhibition; may be combined with docking or other in silico filters (not detailed in the review excerpt).</td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_metric_name</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_validation_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>ground_truth_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>explicit_gap_measurement</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_positive_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>false_negative_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>has_both_proxy_and_ground_truth</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>validation_performed</strong></td>
                            <td>computational only (as described in the summary; the review does not state experimental follow-up in the excerpt)</td>
                        </tr>
                        <tr>
                            <td><strong>number_predictions_made</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>number_experimentally_validated</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discovery_novelty</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>extrapolation_distance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>proxy_bias_correction_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cost_time</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>domain_maturity</strong></td>
                            <td>emerging application of ML to drug repurposing; methods exist but experimental confirmation typically required for translation.</td>
                        </tr>
                        <tr>
                            <td><strong>proxy_failure_modes</strong></td>
                            <td>General ML/repurposing limitations noted in the review (dataset bias, overfitting, lack of interpretability) but no contribution-specific failure-mode metrics provided.</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_calibration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>multiple_proxy_types</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>validation_cascade</strong></td>
                            <td>computational virtual screening / repurposing prioritization (no experimental cascade described in excerpt).</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_baseline</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>domain_specific_factors</strong></td>
                            <td>training data bias toward well-studied compounds and limited experimental activity data can impair ML generalization and produce false positives/negatives.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Quality Assessment of Selected Protein Structures Derived from Homology Modeling and AlphaFold <em>(Rating: 2)</em></li>
                <li>Antimicrobial Evaluation of Sulfonamides after Coupling with Thienopyrimidine Coplanar Structure <em>(Rating: 2)</em></li>
                <li>Network Pharmacology and Experimental Validation to Explore the Potential Mechanism of Nigella sativa for the Treatment of Breast Cancer <em>(Rating: 2)</em></li>
                <li>AutoPepVax, a Novel Machine-Learning-Based Program for Vaccine Design: Application to a Pan-Cancer Vaccine Targeting EGFR Missense Mutations <em>(Rating: 1)</em></li>
                <li>Machine Learning-Assisted Drug Repurposing Framework for Discovery of Aurora Kinase B Inhibitors <em>(Rating: 1)</em></li>
                <li>Identification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations <em>(Rating: 1)</em></li>
            </ol>
        </div>

        <div class="section">
            <h2>Extracted Data (Debug)</h2>
            <pre><code>{
    "id": "extraction-result-1874",
    "paper_id": "paper-277197795",
    "extraction_schema_id": "extraction-schema-36",
    "extracted_data": [
        {
            "name_short": "AlphaFold / Homology assessment",
            "name_full": "Quality assessment of protein structures derived from homology modeling versus AlphaFold predictions",
            "brief_description": "A comparative evaluation of homology modeling and AlphaFold deep-learning structural predictions against experimental structural data, identifying cases where AlphaFold predictions diverge from experiment and arguing for hybrid computational–experimental validation.",
            "citation_title": "Quality Assessment of Selected Protein Structures Derived from Homology Modeling and AlphaFold",
            "mention_or_use": "mention",
            "system_name": "AlphaFold (deep-learning structure prediction) and homology-modeling pipelines",
            "domain": "structural biology / protein modeling",
            "proxy_metric_name": "predicted 3D protein structure quality (model coordinates, predicted confidence metrics such as pLDDT/pTM or analogous per-residue confidence scores) / similarity metrics between predicted and experimental structures (e.g., RMSD, global similarity)",
            "proxy_metric_type": "data-driven ML model (AlphaFold) and empirical homology-modeling (template-based modeling)",
            "proxy_metric_description": "AlphaFold generates 3D coordinates from amino-acid sequence using a deep-learning model trained on structural databases; homology modeling generates structures by aligning target sequences to known template structures and building models by template-based reconstruction. Quality is assessed by predicted confidence scores (AlphaFold per-residue confidence) and by structural-comparison metrics when experimental structures exist.",
            "ground_truth_metric_name": "experimentally determined 3D structures (X-ray crystallography / NMR / cryo-EM coordinates) and structure similarity metrics (RMSD, local/global agreement)",
            "ground_truth_validation_method": "comparison of in silico 3D model coordinates to experimental structural coordinates (alignment and calculation of structure-similarity metrics), i.e., direct structural benchmarking against deposited experimental structures",
            "proxy_performance": null,
            "ground_truth_performance": null,
            "explicit_gap_measurement": "Paper reports that there are identified cases where AlphaFold fails to match experimental data (qualitative statement); no quantitative aggregate gap measurements reported in this review text.",
            "false_positive_rate": null,
            "false_negative_rate": null,
            "has_both_proxy_and_ground_truth": true,
            "validation_performed": "computational + comparison to experimental structures (computational benchmarking against experimental ground-truth)",
            "number_predictions_made": null,
            "number_experimentally_validated": null,
            "discovery_novelty": null,
            "extrapolation_distance": null,
            "proxy_bias_correction": null,
            "proxy_bias_correction_method": null,
            "validation_cost_time": null,
            "domain_maturity": "mixed — deep-learning structure prediction (AlphaFold) is mature and widely used but has recognized limitations; homology modeling is established but limited by template availability",
            "proxy_failure_modes": "Instances where AlphaFold predictions do not match experimental structures are discussed; the review emphasizes limitations of structural modeling and the need for hybrid computational–experimental validation (qualitative failure-mode identification rather than quantified modes).",
            "uncertainty_quantification": true,
            "uncertainty_calibration": "AlphaFold provides per-residue confidence scores (implicit); the review notes mismatches with experimental data but does not provide calibrated statistics in the text provided.",
            "multiple_proxy_types": true,
            "validation_cascade": "computational benchmarking against experimentally solved structures (single-stage comparison); no further in vitro/in vivo cascade described in this review excerpt.",
            "comparison_to_baseline": "AlphaFold and homology modeling are compared qualitatively to experimental structures; the review reports cases of AlphaFold failure versus experimental data but does not present numeric baseline comparisons in the excerpt.",
            "domain_specific_factors": "limitations arise from issues in structural modeling such as regions with poor templates, conformational heterogeneity, or contexts not captured in training data; review emphasizes need for hybrid computational-experimental approaches.",
            "uuid": "e1874.0"
        },
        {
            "name_short": "In silico → experimental antimicrobial pipeline",
            "name_full": "In silico screening against target enzymes followed by experimental antimicrobial assays for thienopyrimidine–sulfonamide hybrids",
            "brief_description": "A workflow where in silico docking/screening against target microbial enzymes prioritized candidates, and the selected hybrid compounds were subsequently synthesized and validated in experimental antimicrobial and antifungal assays.",
            "citation_title": "Antimicrobial Evaluation of Sulfonamides after Coupling with Thienopyrimidine Coplanar Structure",
            "mention_or_use": "mention",
            "system_name": "In silico docking/virtual screening pipeline (structure-based virtual screening against microbial target enzymes)",
            "domain": "antibacterial / antifungal drug discovery",
            "proxy_metric_name": "docking score / predicted binding affinity to target enzyme(s) from molecular docking",
            "proxy_metric_type": "physics-based simulation (molecular docking) / empirical scoring functions",
            "proxy_metric_description": "Virtual screening/docking calculations against target enzymes produce poses and docking scores (binding-energy–like scores) used to rank candidate hybrid molecules; these computational metrics guide selection prior to synthesis.",
            "ground_truth_metric_name": "experimental antimicrobial / antifungal activity (in vitro microbiological assays)",
            "ground_truth_validation_method": "wet-lab synthesis of selected compounds followed by standard antimicrobial/antifungal assays (e.g., growth-inhibition assays, MIC determination) — described as experimental validation in the contribution summary.",
            "proxy_performance": null,
            "ground_truth_performance": null,
            "explicit_gap_measurement": null,
            "false_positive_rate": null,
            "false_negative_rate": null,
            "has_both_proxy_and_ground_truth": true,
            "validation_performed": "computational + experimental synthesis and activity testing (in vitro)",
            "number_predictions_made": null,
            "number_experimentally_validated": null,
            "discovery_novelty": null,
            "extrapolation_distance": null,
            "proxy_bias_correction": null,
            "proxy_bias_correction_method": null,
            "validation_cost_time": null,
            "domain_maturity": "well-established workflow in medicinal chemistry — structure-based virtual screening followed by in vitro validation is a standard pipeline, though predictive accuracy varies by target and scoring function.",
            "proxy_failure_modes": "Not explicitly quantified in the review; implicit failure modes include docking false positives (compounds with good docking scores but poor experimental activity) and scoring-function limitations — the contribution used experimental assays to validate candidates, illustrating the need for wet-lab confirmation.",
            "uncertainty_quantification": null,
            "uncertainty_calibration": null,
            "multiple_proxy_types": true,
            "validation_cascade": "computational virtual screening → synthesis → in vitro antimicrobial assays (two-stage cascade described qualitatively).",
            "comparison_to_baseline": null,
            "domain_specific_factors": "target enzyme choice, scoring-function limitations, and biological complexity of antimicrobial activity (cell permeability, efflux, metabolism) affect translation from docking score to experimental activity.",
            "uuid": "e1874.1"
        },
        {
            "name_short": "Nigella sativa network pharmacology",
            "name_full": "Network pharmacology predictions for Nigella sativa mechanisms with experimental validation for breast cancer",
            "brief_description": "Network-pharmacology analyses identified candidate intersection genes/targets/pathways for Nigella sativa compounds in breast cancer, followed by experimental validation to test predicted mechanisms.",
            "citation_title": "Network Pharmacology and Experimental Validation to Explore the Potential Mechanism of Nigella sativa for the Treatment of Breast Cancer",
            "mention_or_use": "mention",
            "system_name": "Network pharmacology pipeline (target/pathway prediction from compound–target networks and enrichment analyses)",
            "domain": "network pharmacology / natural-product drug discovery / oncology",
            "proxy_metric_name": "network-derived target/pathway scores (e.g., connectivity, enrichment p-values, predicted target engagement from network topology)",
            "proxy_metric_type": "data-driven bioinformatic network analysis (computational inference from known compound–target and gene–disease associations)",
            "proxy_metric_description": "Computational integration of compound-target databases, gene-expression or disease-gene associations, and pathway enrichment analyses to predict relevant molecular targets and mechanisms for Nigella sativa constituents relevant to breast cancer.",
            "ground_truth_metric_name": "experimental validation metrics (e.g., in vitro assays measuring cellular viability, target modulation, biochemical assays validating predicted targets/pathways)",
            "ground_truth_validation_method": "wet-lab experiments testing predicted mechanisms and effects (in vitro cellular or molecular assays as described in the contribution title and summary).",
            "proxy_performance": null,
            "ground_truth_performance": null,
            "explicit_gap_measurement": null,
            "false_positive_rate": null,
            "false_negative_rate": null,
            "has_both_proxy_and_ground_truth": true,
            "validation_performed": "computational network pharmacology + experimental validation (in vitro)",
            "number_predictions_made": null,
            "number_experimentally_validated": null,
            "discovery_novelty": null,
            "extrapolation_distance": null,
            "proxy_bias_correction": null,
            "proxy_bias_correction_method": null,
            "validation_cost_time": null,
            "domain_maturity": "established computational strategy in natural-product research, but translation to experimental confirmation remains challenging due to biological complexity.",
            "proxy_failure_modes": "Not quantified in the review; general limitations include false positive pathway/target predictions owing to database incompleteness or pleiotropic effects, requiring experimental follow-up.",
            "uncertainty_quantification": null,
            "uncertainty_calibration": null,
            "multiple_proxy_types": true,
            "validation_cascade": "computational network analysis → targeted experimental validation (qualitative two-stage pipeline).",
            "comparison_to_baseline": null,
            "domain_specific_factors": "multi-target nature of natural products, pathway redundancy, and complexities of cellular phenotypes influence proxy-to-ground-truth translation.",
            "uuid": "e1874.2"
        },
        {
            "name_short": "AutoPepVax",
            "name_full": "AutoPepVax, a machine-learning-based program for vaccine epitope design (application to pan-cancer EGFR missense mutations)",
            "brief_description": "An ML-driven epitope selection framework using random-forest classification and linear regression to predict epitope safety, efficacy, and population applicability for vaccine design, demonstrated on EGFR missense mutations as a pan-cancer vaccine target.",
            "citation_title": "AutoPepVax, a Novel Machine-Learning-Based Program for Vaccine Design: Application to a Pan-Cancer Vaccine Targeting EGFR Missense Mutations",
            "mention_or_use": "mention",
            "system_name": "AutoPepVax (random forest classifier + linear regression models for epitope selection)",
            "domain": "vaccine design / computational immunology",
            "proxy_metric_name": "predicted epitope immunogenicity/safety scores and population-coverage estimates (ML-derived classification/regression outputs)",
            "proxy_metric_type": "data-driven ML models (random forest classification, linear regression)",
            "proxy_metric_description": "Models trained on available epitope/immune-response datasets produce classification labels (predicted safe/immunogenic epitopes) and regression scores (quantitative safety/efficacy predictions); population-coverage optimization performed computationally.",
            "ground_truth_metric_name": null,
            "ground_truth_validation_method": null,
            "proxy_performance": null,
            "ground_truth_performance": null,
            "explicit_gap_measurement": null,
            "false_positive_rate": null,
            "false_negative_rate": null,
            "has_both_proxy_and_ground_truth": false,
            "validation_performed": "computational only (as reported in this review summary); no explicit wet-lab validation described in the excerpt",
            "number_predictions_made": null,
            "number_experimentally_validated": null,
            "discovery_novelty": null,
            "extrapolation_distance": null,
            "proxy_bias_correction": null,
            "proxy_bias_correction_method": null,
            "validation_cost_time": null,
            "domain_maturity": "emerging ML-driven vaccine-design methods; incorporation of ML is growing but experimental validation is often required to confirm predictions.",
            "proxy_failure_modes": "Review notes general issues in ML models for epitope selection (poor predictive accuracy historically); AutoPepVax aims to address predictive accuracy but no quantitative failure-mode statistics are provided here.",
            "uncertainty_quantification": null,
            "uncertainty_calibration": null,
            "multiple_proxy_types": null,
            "validation_cascade": "computational epitope prediction and population-coverage analysis (no experimental cascade described in excerpt).",
            "comparison_to_baseline": null,
            "domain_specific_factors": "data quality/bias in epitope datasets, class imbalance, and limited experimental immunogenicity data affect ML predictive performance.",
            "uuid": "e1874.3"
        },
        {
            "name_short": "Aurora B ML repurposing",
            "name_full": "Machine learning-assisted drug repurposing framework for discovery of Aurora Kinase B inhibitors",
            "brief_description": "A machine-learning-assisted framework intended to repurpose approved or known compounds as Aurora Kinase B inhibitors by integrating ML-based virtual screening with downstream computational analyses.",
            "citation_title": "Machine Learning-Assisted Drug Repurposing Framework for Discovery of Aurora Kinase B Inhibitors",
            "mention_or_use": "mention",
            "system_name": "Machine learning-assisted drug repurposing pipeline (unspecified ML models for activity prediction and virtual screening)",
            "domain": "drug repurposing / kinase inhibitor discovery",
            "proxy_metric_name": "ML-predicted inhibitory activity scores / repurposing prioritization scores",
            "proxy_metric_type": "data-driven ML model (virtual screening/prediction)",
            "proxy_metric_description": "ML models trained on activity/chemotype data rank existing compounds for predicted Aurora Kinase B inhibition; may be combined with docking or other in silico filters (not detailed in the review excerpt).",
            "ground_truth_metric_name": null,
            "ground_truth_validation_method": null,
            "proxy_performance": null,
            "ground_truth_performance": null,
            "explicit_gap_measurement": null,
            "false_positive_rate": null,
            "false_negative_rate": null,
            "has_both_proxy_and_ground_truth": false,
            "validation_performed": "computational only (as described in the summary; the review does not state experimental follow-up in the excerpt)",
            "number_predictions_made": null,
            "number_experimentally_validated": null,
            "discovery_novelty": null,
            "extrapolation_distance": null,
            "proxy_bias_correction": null,
            "proxy_bias_correction_method": null,
            "validation_cost_time": null,
            "domain_maturity": "emerging application of ML to drug repurposing; methods exist but experimental confirmation typically required for translation.",
            "proxy_failure_modes": "General ML/repurposing limitations noted in the review (dataset bias, overfitting, lack of interpretability) but no contribution-specific failure-mode metrics provided.",
            "uncertainty_quantification": null,
            "uncertainty_calibration": null,
            "multiple_proxy_types": null,
            "validation_cascade": "computational virtual screening / repurposing prioritization (no experimental cascade described in excerpt).",
            "comparison_to_baseline": null,
            "domain_specific_factors": "training data bias toward well-studied compounds and limited experimental activity data can impair ML generalization and produce false positives/negatives.",
            "uuid": "e1874.4"
        }
    ],
    "potentially_relevant_new_papers": [
        {
            "paper_title": "Quality Assessment of Selected Protein Structures Derived from Homology Modeling and AlphaFold",
            "rating": 2
        },
        {
            "paper_title": "Antimicrobial Evaluation of Sulfonamides after Coupling with Thienopyrimidine Coplanar Structure",
            "rating": 2
        },
        {
            "paper_title": "Network Pharmacology and Experimental Validation to Explore the Potential Mechanism of Nigella sativa for the Treatment of Breast Cancer",
            "rating": 2
        },
        {
            "paper_title": "AutoPepVax, a Novel Machine-Learning-Based Program for Vaccine Design: Application to a Pan-Cancer Vaccine Targeting EGFR Missense Mutations",
            "rating": 1
        },
        {
            "paper_title": "Machine Learning-Assisted Drug Repurposing Framework for Discovery of Aurora Kinase B Inhibitors",
            "rating": 1
        },
        {
            "paper_title": "Identification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations",
            "rating": 1
        }
    ],
    "cost": 0.013978499999999998,
    "model_str": "gpt-5-mini"
}</code></pre>
        </div>
        <div class="section">
            <h2>Paper</h2>
            <div class="paper-content"><p>Computer-Aided Drug Design and Drug Discovery
20 March 2025</p>
<p>Paul Dragos 
Faculty of Pharmacy
"Carol Davila" University of Medicine and Pharmacy
Traian Vuia 6020956BucharestRomania</p>
<p>Mihai 0000-0003-2880-9381
Faculty of Pharmacy
"Carol Davila" University of Medicine and Pharmacy
Traian Vuia 6020956BucharestRomania</p>
<p>George Mihai Nitulescu george.nitulescu@umfcd.ro 
Faculty of Pharmacy
"Carol Davila" University of Medicine and Pharmacy
Traian Vuia 6020956BucharestRomania</p>
<p>Computer-Aided Drug Design and Drug Discovery
20 March 202515E9D7A5DDBD84D80141B12B42815F9610.3390/ph18030436Received: 28 February 2025 Accepted: 14 March 2025</p>
<p>In the rapidly evolving landscape of pharmaceutical research, the integration of computational methods has become a cornerstone in drug discovery and development efforts.Computer-aided drug design (CADD) offers a more efficient and cost-effective approach, complementing traditional experimental techniques.By leveraging computational tools such as molecular modeling, structure-activity relationships, and virtual screening, researchers can predict the behavior of drug candidates, assess their interactions with biological targets, and optimize their pharmacokinetic properties before synthesis and experimental validation [1][2][3][4][5].</p>
<p>Over the past few decades, CADD has transitioned from a supplementary tool to a central component in drug discovery pipelines.The realm of drug discovery has been significantly transformed by the advent of CADD, which integrates computational tools with traditional pharmacological methods to streamline the discovery and development of novel therapeutic agents [6][7][8][9][10].</p>
<p>This Special Issue ("Computer-Aided Drug Design and Drug Discovery") aims to showcase some of the latest advancements in this interdisciplinary field, highlighting the applications of computational approaches in accelerating the identification and optimization of therapeutic agents [11,12].By exploiting machine learning (ML) and artificial intelligence (AI) algorithms [7], this issue seeks to contribute to the development of cutting-edge methodologies for drug design and discovery [10].</p>
<p>Despite the rapid evolution of CADD and its integration into modern drug discovery, several key limitations and challenges remain unaddressed.These gaps highlight the need for further advancements to optimize the efficiency, reliability, and applicability of computational drug design methodologies.</p>
<p>One of the biggest challenges in CADD is the availability and quality of biological and chemical datasets.Many datasets used for training AI models in drug discovery are proprietary, incomplete, or biased toward well-studied compounds, leading to reduced predictive accuracy [13].Additionally, integrating large-scale biological data such as genomics, proteomics, and metabolomics (multi-omics integration) remains a significant challenge due to standardization issues [14].Existing computational frameworks struggle to effectively incorporate these data types into drug design pipelines.Moreover, the lack of standardized bioinformatics tools for integrating diverse datasets hinders the development of precision medicine approaches [15].</p>
<p>While AI and ML have transformed CADD, many predictive models suffer from overfitting, lack of interpretability, and insufficient generalizability across different chemical spaces [2].These limitations often lead to inaccurate predictions of molecular binding affinities and pharmacokinetic properties [15].</p>
<p>Despite technological advancements, high-performance computing (HPC) and quantum computing remain underutilized in CADD due to cost constraints and limited accessi-bility [13].Many small research institutions and startups lack access to the computational resources needed for large-scale molecular simulations [14].</p>
<p>The use of AI in drug discovery also raises ethical and regulatory concerns, including bias in AI models, reproducibility of results, and the validation of AI-predicted drug candidates in clinical trials [16].Additionally, there is a lack of clear regulatory frameworks for AI-driven drug discovery approaches [17].</p>
<p>This Special Issue directly tackles many of the key gaps in knowledge identified in CADD.The published papers showcase advancements in predictive modeling, drug repurposing, molecular docking, and machine learning-driven discovery, demonstrating how computational methodologies can overcome existing limitations in data availability, predictive accuracy, and multi-target drug discovery.</p>
<p>A comprehensive review by Niazi and Mariam (Contribution 1) traces the historical evolution of CADD, delineates its methodologies into structure-based and ligand-based approaches, and discusses its pivotal role in modern drug discovery.The paper also addresses current challenges, including the integration of AI and ML, data privacy concerns, and the need for robust ethical frameworks.Another review (Contribution 2) highlights the successful application of computational approaches in identifying novel SIRT1/2 modulators, providing a detailed analysis of ligand and structure-based methods employed in recent discoveries.</p>
<p>Several studies in this Special Issue have introduced novel methodologies to enhance model reliability.One study illustrates the development of an advanced ML-based framework for epitope selection in vaccine design, addressing the challenge of poor predictive accuracy in peptide vaccine development.By employing random forest classification and linear regression models, this study demonstrates how improved algorithms can optimize epitope safety and efficacy while ensuring population-wide vaccine applicability (Contribution 4) [18].Another study showcases how QSAR modeling, molecular docking, and molecular dynamics simulations can be combined to repurpose existing drugs for new therapeutic uses (Contribution 21) [19].</p>
<p>Traditional drug discovery often fails to address multi-domain proteins or diseases with complex pathologies.One study (Contribution 5) highlighted the virtual screening of inhibitors that simultaneously bind multiple domains within protein tyrosine kinase 6 (PTK6), potentially improving inhibitor efficacy and specificity.Another study addresses drug resistance issues in acute myeloid leukemia (AML) by using molecular docking and molecular dynamics simulations to identify inhibitors that target a mutant isocitrate dehydrogenase 1 (mIDH1) variant (Contribution 10), demonstrating how CADD can lead to the discovery of second-generation inhibitors to counteract resistance mutations.</p>
<p>The reliability of structural modeling remains a significant challenge in CADD, particularly in homology modeling and deep-learning-based structure predictions.One paper featured in this Issue critically evaluates these methodologies and provides insights into their limitations.Homology modeling was assessed against deep learning-based AlphaFold 3D structure predictions [20].The study identified cases where AlphaFold fails to match experimental data, emphasizing the need for hybrid computational-experimental validation approaches.</p>
<p>The COVID-19 pandemic has highlighted the need for rapid antiviral drug discovery, yet computational screening for antiviral compounds remains an underexplored area.One paper in this Issue addresses how CADD can accelerate the identification of antiviral agents by using molecular docking, network pharmacology, and bioinformatic tools to explore natural product-based antiviral mechanisms against SARS-CoV-2 (Contribution 3).</p>
<p>Another work describes the design, synthesis, and activity assessment of antibacterial and antifungal hybrid compounds combining thienopyrimidine and sulfonamide scaf-folds (Contribution 7).In silico screening against target enzymes guided the selection of promising candidates, which were subsequently validated through experimental assays.</p>
<p>Collectively, the papers published in this Special Issue underscore the transformative impact of computational approaches in drug discovery.The integration of AI and machine learning further enhances these capabilities, enabling the analysis of complex datasets and the generation of predictive models that inform decision-making in drug development.</p>
<p>Despite the presented advancements, several challenges remain unresolved in the field of CADD.Future research should focus on significantly improving the accuracy of predictive models, addressing biases in AI algorithms, and ensuring the integration of diverse biological data.
 Funding: This research received no external funding.Data Availability Statement: Data are contained in this article.Conflicts of Interest:The authors declare no conflicts of interest.List of Contributions
Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis. S K Niazi, Z Mariam, 10.3390/ph17010022Pharmaceuticals. 17222024</p>
<p>Recent Advances in the Discovery of SIRT1/2 Inhibitors via Computational Methods: A Perspective. N Scarano, C Brullo, F Musumeci, E Millo, S Bruzzone, S Schenone, E Cichero, 10.3390/ph17050601Pharmaceuticals. 176012024</p>
<p>Anti-Viral Activity of Bioactive Molecules of Silymarin against COVID-19 via In Silico Studies. C Zhang, Y Sui, S Liu, M Yang, 10.3390/ph16101479Pharmaceuticals. 1614792023</p>
<p>Quality Assessment of Selected Protein Structures Derived from Homology Modeling and AlphaFold. F A Binbay, D C Rathod, A A P George, D Imhof, 10.3390/ph16121662Pharmaceuticals. 1616622023</p>
<p>Y Zhou, M W Wong, 10.3390/ph17010060Silico Screening of Multi-Domain Targeted Inhibitors for PTK6: A Strategy Integrating Drug Repurposing and Consensus Docking. 20241760</p>
<p>Exploring Potentilla nepalensis Phytoconstituents: Integrated Strategies of Network Pharmacology, Molecular Docking, Dynamic Simulations, and MMGBSA Analysis for Cancer Therapeutic Targets Discovery. M Praveen, I Ullah, R Buendia, I A Khan, M G Sayed, R Kabir, M A Bhat, M Yaseen, 10.3390/ph17010134Pharmaceuticals. 171342024</p>
<p>Antimicrobial Evaluation of Sulfonamides after Coupling with Thienopyrimidine Coplanar Structure. E I Elmongy, W S Alanazi, A I Aldawsari, A A Alfaouri, R Binsuwaidan, 10.3390/ph17020188Pharmaceuticals. 171882024</p>
<p>Shaping the Future of Obesity Treatment: In Silico Multi-Modeling of IP6K1 Inhibitors for Obesity and Metabolic Dysfunction. I Mondal, A K Halder, N Pattanayak, S K Mandal, M N D S Cordeiro, 10.3390/ph17020263Pharmaceuticals. 172632024</p>
<p>A Apan, D Casoni, D Leonte, C Pop, I Iaru, An Mogos, C Zaharia, V , 10.3390/ph17030295The Drug-Likeness Analysis of Anti-Inflammatory Thiazolo. 202452295Heterocycles</p>
<p>Identification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations. W Zhang, H Bai, Y Wang, X Wang, R Jin, H Guo, H Lai, Y Tang, Y Wang, 10.3390/ph17030336Pharmaceuticals. 173362024</p>
<p>AutoPepVax, a Novel Machine-Learning-Based Program for Vaccine Design: Application to a Pan-Cancer Vaccine Targeting EGFR Missense Mutations. E Bautista, Y H Jung, M Jaramillo, H Ganesh, A Varma, K Savsani, S Dakshanamurthy, 10.3390/ph17040419Pharmaceuticals. 174192024</p>
<p>Investigating Potential Cancer Therapeutics: Insight into Histone Deacetylases (HDACs) Inhibitions. B Ahmad, A Saeed, A Al-Amery, I Celik, I Ahmed, M Yaseen, I A Khan, D Al-Fahad, M A Bhat, 10.3390/ph17040444Pharmaceuticals. 174442024</p>
<p>A Ajmal, M Danial, M Zulfat, M Numan, S Zakir, C Hayat, K F Alabbosh, M E A Zaki, A Ali, D Wei, 10.3390/ph17050551Silico Prediction of New Inhibitors for Kirsten Rat Sarcoma G12D Cancer Drug Target Using Machine Learning-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulation Approaches. 202417551</p>
<p>Network Pharmacology and Experimental Validation to Explore the Potential Mechanism of Nigella sativa for the Treatment of Breast Cancer. R Arif, S A Bukhari, G Mustafa, S Ahmed, M F Albeshr, 10.3390/ph17050617Pharmaceuticals. 176172024</p>
<p>Discovery of Novel Allosteric SHP2 Inhibitor Using Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Principal Component Analysis. P Singh, V Kumar, K W Lee, J C Hong, 10.3390/ph17070935Pharmaceuticals. 179352024</p>
<p>Do Molecular Fingerprints Identify Diverse Active Drugs in Large-Scale Virtual Screening? Pharmaceuticals. V Venkatraman, J Gaiser, D Demekas, A Roy, R Xiong, T J Wheeler, 10.3390/ph17080992202417992</p>
<p>Network Pharmacology Identifies Intersection Genes of Apigenin and Naringenin in Down Syndrome as Potential Therapeutic Targets. M Amir, S Shafi, S Parveen, A A Reshi, A Ahmad, 10.3390/ph17081090Pharmaceuticals. 1710902024</p>
<p>Computational Design and Optimization of Peptide Inhibitors for SIRT2. H A Alkhatabi, F M A Naemi, R Alsolami, H N Alatyb, 10.3390/ph17091120Pharmaceuticals. 1711202024</p>
<p>Exploring the Antiviral Potential of Artemisia annua Through JAK-STAT Pathway Targeting: A. M Ouassaf, L Bourougaa, F Bahaz, B Y Alhatlani, 10.3390/ph17111539Network Pharmacology Approach. Pharmaceuticals. 1715392024</p>
<p>Silico Evaluation of Some Computer-Designed Fluoroquinolone-Glutamic Acid Hybrids as Potential Topoisomerase II Inhibitors with Anti-Cancer Effect. O.-L Oancea, S Gâz, . A Marc, G Lungu, I.-A Rusu, A , 10.3390/ph17121593Pharmaceuticals. 1715932024</p>
<p>. G N D Ion, G M Nitulescu, D P Mihai, 10.3390/ph18010013Machine Learning-Assisted Drug Repurposing Framework for Discovery of Aurora Kinase B Inhibitors. Pharmaceuticals. 18132025</p>
<p>Modern Tools and Techniques in Computer-Aided Drug Design. T Anwar, P Kumar, A U Khan, 10.1016/B978-0-12-822312-3.00011-4Molecular Docking for Computer-Aided Drug Design: Fundamentals, Techniques, Resources, and Applications. Amsterdam, The NetherlandsElsevier2021</p>
<p>Deep Machine Learning for Computer-Aided Drug Design. J Bajorath, 10.3389/fddsv.2022.829043Front. Drug Discov. 2022, 2, 829043. [CrossRef</p>
<p>Revolutionizing Drug Discovery: A Comprehensive Review of Computer-Aided Drug Design Approaches. B Oli, 10.22214/ijraset.2024.63563Int. J. Res. Appl. Sci. Eng. Technol. 122024</p>
<p>Advances in Computer-Aided Drug Design for Type 2 Diabetes. W Huang, L Zhang, Z Li, 10.1080/17460441.2022.2047644Expert Opin. Drug Discov. 172022</p>
<p>Computer-Aided Drug Design: Drug Discovery, Computational Modelling, and Artificial Intelligence. F Ye, M Lin, J Jin, S Broussy, 10.3389/fchem.2022.968687Front. Chem. 109686872022</p>
<p>Grand Challenges of Computer-Aided Drug Design: The Road Ahead. J L Medina-Franco, Front. Drug Discov. 2021, 1, 728551</p>
<p>Computer-Aided Drug Design Using the Fragment Molecular Orbital Method: Current Status and Future Applications for SBDD. D Takaya, 10.1248/cpb.c23-00839Chem. Pharm. Bull. 722024</p>
<p>An Updated Review of Computer-Aided Drug Design and Its Application to COVID-19. A B Gurung, M A Ali, J Lee, M A Farah, K M Al-Anazi, 10.1155/2021/8853056BioMed Res. Int. 88530562021. 2021</p>
<p>An Updated Review on Developing Small Molecule Kinase Inhibitors Using Computer-Aided Drug Design Approaches. L Li, S Liu, B Wang, F Liu, S Xu, P Li, Y Chen, 10.3390/ijms241813953Int. J. Mol. Sci. 242023. 13953</p>
<p>Big Data and Artificial Intelligence (AI) Methodologies for Computer-Aided Drug Design (CADD). J W Lee, M A Maria-Solano, T N L Vu, S Yoon, S Choi, 10.1042/BST20211240Biochem. Soc. Trans. 2022. 50</p>
<p>Computer-Aided Drug Design towards New Psychotropic and Neurological Drugs. G Dorahy, J Z Chen, T Balle, 10.3390/molecules28031324Molecules. 282023. 1324</p>
<p>Combating Diseases with Computational Strategies Used for Drug Design and Discovery. F R Makhouri, J B Ghasemi, 10.2174/1568026619666190121125106Curr. Top. Med. Chem. 182018</p>
<p>The New Era of Drug Discovery: The Power of Computer-Aided Drug Design (CADD). I J D S Nascimento, T M De Aquino, E F Da Silva-Júnior, 10.2174/1570180819666220405225817Lett. Drug Des. Discov. 192022</p>
<p>An Innovative Multi-Omics Model Integrating Latent Alignment and Attention Mechanism for Drug Response Prediction. H.-O Chen, Y.-C Cui, P.-C Lin, J.-H Chiang, 10.3390/jpm14070694J. Pers. Med. 142024</p>
<p>Challenge-Enabled Machine Learning to Drug-Response Prediction. Z Wang, H Li, C Carpenter, Y Guan, 10.1208/s12248-020-00494-5AAPS J. 222020</p>
<p>Computer Aided Drug Design: An Overview. S Surabhi, B Singh, 10.22270/jddt.v8i5.1894J. Drug Deliv. Ther. 82018</p>
<p>Current Perspectives and Trend of Computer-Aided Drug Design: A Review and Bibliometric Analysis. Z Wu, S Chen, Y Wang, F Li, H Xu, M Li, Y Zeng, Z Wu, Y Gao, 10.1097/JS9.0000000000001289Int. J. Surg. 1102024</p>
<p>AutoPepVax, a Novel Machine-Learning-Based Program for Vaccine Design: Application to a Pan-Cancer Vaccine Targeting EGFR Missense Mutations. E Bautista, Y H Jung, M Jaramillo, H Ganesh, A Varma, K Savsani, S Dakshanamurthy, 10.3390/ph17040419Pharmaceuticals. 174192024</p>
<p>. G N D Ion, G M Nitulescu, D P Mihai, 10.3390/ph18010013Machine Learning-Assisted Drug Repurposing Framework for Discovery of Aurora Kinase B Inhibitors. Pharmaceuticals. 182025</p>
<p>Quality Assessment of Selected Protein Structures Derived from Homology Modeling and AlphaFold. F A Binbay, D C Rathod, A A P George, D Imhof, 10.3390/ph16121662Pharmaceuticals. 162023. 1662</p>
<p>Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods. instructions or products referred to in the content</p>            </div>
        </div>

    </div>
</body>
</html>